{"disease":{"id":"braf-v600-wild-type","name":"braf v600 wild type"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03273153","title":"A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":446,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03175432","title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}